ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2312

National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
Abstract Number: 0260

National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
Abstract Number: 2038

Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection
Abstract Number: 0258

Nationwide Analysis of Adult Non-Gonococcal Bacterial Septic Arthritis Hospitalizations from the National Inpatient Sample 2016 to 2020
Abstract Number: 2399

Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization
Abstract Number: 1872

Nationwide Analysis of Prosthetic Joint Complications with and Without Inflammatory Arthritis
Abstract Number: 1394

Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Abstract Number: 1747

Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Abstract Number: 1443

Natural Course of Degenerative Lesions of the Spine on Radiographs and MRI in Axial SpondyloarthritisFollowed 10 Years in the DESIR Cohort
Abstract Number: 0109

Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: L10

Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
Abstract Number: 0948

Neuronal Intestinal Dysplasia Due to Ncx Gene Deficiency Attenuates the Severity of Experimental Arthritis in Mice
Abstract Number: 2547

Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Abstract Number: 2406

Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
Abstract Number: 1321

Neuropsychological Evaluation of Cognitive Impairment in Patients with Rheumatic Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].